A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.

Molecular profiling and prognosis of spindle cell/sclerosing rhabdomyosarcoma: A report from the Chinese PPOG trial. A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...

Chimeric antigen receptor T-cell therapy real-world assessment of total cost of care and clinical events for the treatment of relapsed or refractory lymphoma. Bruton tyrosine kinase inhibitors (BTKi) ...

Relapse prevention is why most people seek treatment, and with opioid use disorders (OUDs), there’s about a 90 percent relapse rate. This article explains why and how specific sayings from self-help ...